Healthcare / Medical DevicesStockholm
$3.86
-0.27 (-6.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-8.0M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$63M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-20.9%
↓Gross Margin
64.8%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.8%
FCF CAGR
—
FCF margin
-33.3%
FCF / Net income
1.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $24.0M · net income $-7.2M · FCF $-8.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $24.0M | $24.0M | $28.2M | $25.0M | $14.3M |
| Net Income | $-7.2M | $-7.2M | $342000.00 | $-4.5M | $-8.8M |
| EBITDA | $-6.5M | $-6.5M | $444000.00 | $-4.4M | $-8.6M |
| EPS | — | — | 0.02 | -0.32 | -0.62 |
| Gross Margin | 64.8% | 64.8% | 64.2% | 52.6% | 78.5% |
| Operating Margin | -30.7% | -30.7% | 0.7% | -20.3% | -71.2% |
| Net Margin | -29.9% | -29.9% | 1.2% | -18.1% | -61.1% |
| Balance Sheet | |||||
| Current Ratio | 5.39 | 5.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.0M | $-8.0M | $-8.8M | $-5.7M | $-12.2M |
| Returns | |||||
| ROE | -20.9% | -20.9% | 0.9% | -19.5% | -32.3% |
| Valuation | |||||
| P/E | — | — | 350.00 | — | — |
| EV/EBITDA | — | — | 235.01 | — | — |
| P/B | 1.85 | 1.85 | 3.02 | 4.56 | 5.17 |
| Growth & Yield | |||||
| Revenue Growth | -14.7% | -14.7% | 12.9% | 74.1% | — |
| EPS Growth | — | — | 106.2% | 48.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.02 → n/d
Residual
-35.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.